How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Cohere Inc. chief executive Aidan Gomez is criticizing calls from top leaders in artificial intelligence to slow the pace of ...

OpenAI and Anthropic researchers are urging a slowdown in advanced AI development over catastrophic-risk concerns. They cite ...

Alarm grew after a researcher resigned, warning that the “people building AI earnestly believe that it could kill us all by ...

Chief scientist Jakub Pachocki said it won’t be long until artificial intelligence models can also improve themselves without ...

Apparently, folding is only Apple's warm-up stretch. Yesterday, Apple secured US patent 12,730,478 B2 detailing a stretchable ...

The researcher warned that AI leaders sincerely believe the technology could kill all of humanity by the decade’s end, saying it’s not a ’marketing stunt.’ ...

Anthropic CEO Dario Amodei is calling on artificial intelligence companies to slow the development of their most advanced models, a proposal that has drawn support from several other industry leaders.